FDA Lifts Clinical Hold on Simufilam, Clearing Path for Phase 2a Epilepsy Trial
FLNA is trading near its 52-week low of $0.67 (8.5% above the low).
Summary
The FDA lifted the full clinical hold on Filana's simufilam IND on September 22, 2026, allowing the company to proceed with a planned Phase 2a proof-of-concept study in TSC-related epilepsy. Filana engaged a leading CRO, identified trial sites, and is recruiting investigators, with patient screening expected to begin in Q1 2027 and investigational drug supply in place. The study is a multicenter, randomized, double-blind clinical trial evaluating simufilam in patients with refractory TSC-related seizures, assessing safety, tolerability, pharmacokinetics, seizure frequency, intensity, duration, nighttime seizures, and sleep-related outcomes. The trial will enroll 40 patients aged 12-55 across 13 U.S. sites, testing two doses over 16 weeks with a 48-week extension, and data are expected to inform future studies in younger patient populations. Filana is collaborating with the TSC Alliance and the broader TSC community to support patient engagement and study execution. This removes a major regulatory overhang and validates the company's pivot to TSC-related epilepsy after prior setbacks. With $82.7M in cash as of Q2 2026 and a burn rate of roughly $12.7M per half, Filana has runway to execute this trial. The stock trades at $0.727 with a market cap of about $36M, so this news could drive significant re-rating if investors view the hold lift as de-risking the program.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Filana engaged a leading CRO, identified trial sites, and is recruiting investigators; patient screening expected Q1 2027.
- Trial Design
- The Phase 2a study is a multicenter, randomized, double-blind clinical trial.
- The study will evaluate simufilam in patients with refractory TSC-related seizures.
- The study will assess safety, tolerability, pharmacokinetics, seizure frequency, intensity, duration, nighttime seizures, and sleep-related outcomes.
- Future Studies — Data from the study are expected to inform future studies in younger patient populations.
- Patient Engagement — Filana is collaborating with the TSC Alliance and the broader TSC community to support patient engagement and study execution.
- Drug Supply — Investigational drug supply for the study is in place.
- Mechanism — Simufilam is an oral small molecule intended to modulate the filamin A protein.
All 8 details
- The FDA lifted the full clinical hold on September 22, 2026.
- Investigational drug supply for the study is in place.
- The Phase 2a study is a multicenter, randomized, double-blind clinical trial.
- The study will evaluate simufilam in patients with refractory TSC-related seizures.
- The study will assess safety, tolerability, pharmacokinetics, seizure frequency, intensity, duration, nighttime seizures, and sleep-related outcomes.
- Data from the study are expected to inform future studies in younger patient populations.
- Filana is collaborating with the TSC Alliance and the broader TSC community to support patient engagement and study execution.
- Simufilam is an oral small molecule intended to modulate the filamin A protein.
- Trial Design
At the time of this announcement, FLNA was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.7M. The 52-week trading range was $0.67 to $4.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.